Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib

IMPORTANCE: Gastrointestinal stromal tumors (GISTs) are life-threatening when metastatic or not amenable to surgical removal. In a few patients with advanced GISTs refractory to imatinib mesylate, treatment with sunitinib malate followed by regorafenib provides tumor control; however, additional act...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Principais autores: Schuetze, Scott M., Bolejack, Vanessa, Thomas, Dafydd G., von Mehren, Margaret, Patel, Shreyaskumar, Samuels, Brian, Choy, Edwin, D’Amato, Gina, Staddon, Arthur P., Ganjoo, Kristen N., Chow, Warren A., Rushing, Daniel A., Forscher, Charles A., Priebat, Dennis A., Loeb, David M., Chugh, Rashmi, Okuno, Scott, Reinke, Denise K., Baker, Laurence H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6145709/
https://ncbi.nlm.nih.gov/pubmed/29710216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.0601
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados